0.585
0.01 (0.86%)
| Previous Close | 0.580 |
| Open | 0.600 |
| Volume | 67,254 |
| Avg. Volume (3M) | 207,102 |
| Market Cap | 64,512,044 |
| Price / Sales | 83.77 |
| Price / Book | 2.71 |
| 52 Weeks Range | |
| Earnings Date | 21 Aug 2024 |
| Operating Margin (TTM) | -259.14% |
| Diluted EPS (TTM) | -0.070 |
| Quarterly Revenue Growth (YOY) | -1.70% |
| Total Debt/Equity (MRQ) | 2.02% |
| Current Ratio (MRQ) | 7.07 |
| Operating Cash Flow (TTM) | -4.32 M |
| Levered Free Cash Flow (TTM) | -2.05 M |
| Return on Assets (TTM) | -19.70% |
| Return on Equity (TTM) | -33.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | INOVIQ LTD FPO [IIQ] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.38 |
|
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 27.72% |
| % Held by Institutions | 10.49% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |